ACOTEC SCIEN.H. DL-00001 (7W3) - Total Liabilities
Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) has total liabilities worth €392.01 Million EUR (≈ $458.30 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of ACOTEC SCIEN.H. DL-00001 to evaluate the company's liquid asset resilience ratio.
ACOTEC SCIEN.H. DL-00001 - Total Liabilities Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 7W3 asset base.
ACOTEC SCIEN.H. DL-00001 Competitors by Total Liabilities
The table below lists competitors of ACOTEC SCIEN.H. DL-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
|
Turkey | TL4.25 Billion |
|
Oriental Interest Bhd
KLSE:5827
|
Malaysia | RM869.55 Million |
|
BlackRock Investment Quality Municipal Closed Fund
NYSE:BKN
|
USA | $140.98 Million |
|
Viant Technology Inc
NASDAQ:DSP
|
USA | $185.86 Million |
|
Sentral REIT
KLSE:5123
|
Malaysia | RM1.31 Billion |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
USA | $7.36 Million |
|
Angang Steel Company Limited
F:GNV
|
Germany | €50.78 Billion |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
Portugal | €379.82 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ACOTEC SCIEN.H. DL-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 7W3 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACOTEC SCIEN.H. DL-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACOTEC SCIEN.H. DL-00001 (2021–2025)
The table below shows the annual total liabilities of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €392.01 Million ≈ $458.30 Million |
+25.34% |
| 2024-12-31 | €312.76 Million ≈ $365.65 Million |
-0.56% |
| 2023-12-31 | €314.53 Million ≈ $367.72 Million |
+133.93% |
| 2022-12-31 | €134.46 Million ≈ $157.19 Million |
+34.23% |
| 2021-12-31 | €100.17 Million ≈ $117.11 Million |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more